Mark A Yorek Selected Research

AVE 7688

12/2012	Early loss of innervation of cornea epithelium in streptozotocin-induced type 1 diabetic rats: improvement with ilepatril treatment.
2/2012	Effect of inhibition of angiotensin converting enzyme and/or neutral endopeptidase on vascular and neural complications in high fat fed/low dose streptozotocin-diabetic rats.
10/2011	Effect of treatment of high fat fed/low dose streptozotocin-diabetic rats with Ilepatril on vascular and neural complications.
1/2011	Role of the effect of inhibition of neutral endopeptidase on vascular and neural complications in streptozotocin-induced diabetic rats.
1/2011	Effect of Treatment of Sprague Dawley Rats with AVE7688, Enalapril, or Candoxatril on Diet-Induced Obesity.
1/2009	Vascular and neural dysfunctions in obese Zucker rats: effect of AVE7688.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mark A Yorek Research Topics

Disease

25	Peripheral Nervous System Diseases (PNS Diseases) 01/2021 - 12/2007
22	Type 2 Diabetes Mellitus (MODY) 01/2021 - 01/2008
22	Diabetic Neuropathies (Diabetic Neuropathy) 01/2021 - 12/2005
13	Hyperglycemia 01/2020 - 01/2003
7	Obesity 01/2021 - 01/2011
6	Diabetes Complications 08/2013 - 02/2002
5	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2016 - 03/2008
3	Body Weight (Weight, Body) 01/2020 - 01/2016
3	Cardiovascular Diseases (Cardiovascular Disease) 02/2015 - 02/2006
2	Prediabetic State (Prediabetes) 01/2020 - 01/2016
2	Mitochondrial Diseases (Mitochondrial Disease) 06/2017 - 11/2014
2	Insulin Resistance 01/2016 - 10/2011
2	Weight Gain 01/2016 - 01/2016
2	Weight Loss (Weight Reduction) 01/2015 - 12/2011
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2009 - 01/2008
2	Pancreatitis 07/2006 - 01/2004
1	Atrophy 01/2022
1	Neuralgia (Stump Neuralgia) 01/2021
1	Neuroblastoma 01/2021
1	Polyneuropathies (Polyneuropathy) 01/2021
1	Dyslipidemias (Dyslipidemia) 01/2020
1	Disease Progression 01/2020
1	Fatty Liver 01/2012
1	Glucose Intolerance 01/2011
1	Experimental Diabetes Mellitus 01/2011
1	Hypertension (High Blood Pressure) 03/2008

Drug/Important Bio-Agent (IBA)

25	Streptozocin (Streptozotocin)FDA Link 01/2021 - 01/2003
13	Menhaden oilIBA 01/2021 - 01/2012
9	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 10/2015 - 01/2008
7	Neprilysin (Neutral Endopeptidase)IBA 01/2018 - 01/2009
6	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 01/2021 - 07/2015
6	Fish OilsIBA 01/2020 - 07/2015
6	Enalapril FDA LinkGeneric 06/2017 - 01/2008
6	Glucose (Dextrose)FDA LinkGeneric 06/2017 - 02/2002
6	AVE 7688IBA 12/2012 - 01/2009
4	Blood Glucose (Blood Sugar)IBA 01/2020 - 09/2014
4	Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA 01/2020 - 01/2012
4	resolvin D1IBA 01/2018 - 07/2015
4	Pharmaceutical PreparationsIBA 01/2018 - 01/2009
3	LipidsIBA 01/2018 - 01/2008
3	Thioctic Acid (Lipoic Acid)IBA 06/2017 - 10/2015
3	AntioxidantsIBA 10/2015 - 01/2008
3	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 10/2015 - 02/2006
3	Vasopeptidase InhibitorsIBA 12/2012 - 01/2008
3	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 06/2006 - 01/2005
2	NAD (NADH)IBA 01/2021 - 01/2020
2	Arachidonate 15-Lipoxygenase (Arachidonate 15 Lipoxygenase)IBA 01/2021 - 08/2013
2	Insulin (Novolin)FDA Link 01/2020 - 09/2014
2	salicylsalicylic acid (salsalate)IBA 01/2018 - 01/2016
2	Angiotensin Receptor AntagonistsIBA 01/2018 - 02/2006
2	candoxatrilIBA 11/2016 - 01/2011
2	Peroxynitrous Acid (Peroxynitrite)IBA 11/2014 - 12/2007
2	Superoxides (Superoxide)IBA 11/2014 - 01/2005
2	Proteins (Proteins, Gene)FDA Link 11/2014 - 01/2004
2	Acetylcholine (Acetylcholine Chloride)FDA Link 10/2011 - 01/2003
2	Angiotensin Receptors (Angiotensin II Receptor)IBA 01/2008 - 02/2006
2	NF-kappa B (NF-kB)IBA 07/2006 - 01/2004
1	Activating Transcription Factor 4IBA 01/2022
1	Pyruvaldehyde (Methylglyoxal)IBA 01/2021
1	Neuroprotective AgentsIBA 01/2021
1	mitoquinoneIBA 01/2021
1	MagnesiumIBA 01/2021
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2018
1	Docosahexaenoic AcidsIBA 01/2018
1	Unsaturated Dietary FatsIBA 01/2018
1	Dietary Fats (Dietary Fat)IBA 01/2018
1	sacubitril and valsartan sodium hydrate drug combinationIBA 01/2018
1	Pyruvate KinaseIBA 06/2017
1	Messenger RNA (mRNA)IBA 06/2017
1	ML-265IBA 06/2017
1	Reactive Oxygen Species (Oxygen Radicals)IBA 04/2017
1	tempolIBA 04/2017
1	EstersIBA 01/2017
1	Nonesterified Fatty Acids (NEFA)IBA 01/2016
1	nicotinamide-beta-ribosideIBA 01/2016
1	CholesterolIBA 01/2016
1	NADP (NADPH)IBA 01/2016
1	Ophthalmic Solutions (Eye Drops)IBA 01/2016
1	Triglycerides (Triacylglycerol)IBA 01/2016
1	Biomarkers (Surrogate Marker)IBA 01/2016
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 11/2014
1	EnzymesIBA 11/2014
1	Mitogen-Activated Protein KinasesIBA 08/2013
1	Sodium-Hydrogen Exchanger 1IBA 08/2013
1	Sodium-Hydrogen ExchangersIBA 08/2013
1	Lipoxygenase InhibitorsIBA 08/2013
1	AcidsIBA 01/2012
1	AdiponectinIBA 01/2012
1	lardIBA 01/2012
1	baicaleinIBA 12/2011
1	Calcitonin Gene-Related PeptideIBA 10/2011
1	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA 01/2011
1	SodiumIBA 03/2008
1	AngiotensinsIBA 03/2008

Therapy/Procedure

2	Glycemic Control 01/2020 - 09/2014
2	Therapeutics 01/2017 - 10/2015
2	Injections 01/2017 - 07/2015
2	Ligation 07/2006 - 01/2004
1	Aftercare (After-Treatment) 01/2020
1	Caloric Restriction 12/2011